Evidence map›Paper›PMID 40853492›Full record

SynthesisLangenbeck's archives of surgery2025

Clinical prognostic risk assessment of different pathological subtypes of papillary thyroid cancer: a systematic review and network meta-analysis.

Jiayi Zhao, Wanchen Zhang, Dongning Lu, Chengying Shao, Yiwei Chen, Xingyu Huang, Yining Zhang, Jiajie Xu

Abstract readNetwork Meta-AnalysisSystematic Review
In one paragraph

Synthesis in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiayi Zhao *The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Wanchen Zhang *Breast Surgery Department, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Dongning LuThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Chengying ShaoThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yiwei ChenThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Xingyu HuangThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yining ZhangThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Jiajie XuOtolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. xujiajie@hmc.edu.cn.

Funding

Medical and Health Science Research Foundation of Zhejiang Province No. 2021KY482Natural Science Foundation of Zhejiang Province No. LY21H160049the General Scientific Research Project of Education Department of Zhejiang Province No. Y202146111the Traditional Chinese Medicine Science and Technology Project of Zhejiang Province No. 2022ZB020
6 · The paper itself

Abstract

There are multiple pathologic subtypes of papillary thyroid carcinoma (PTC), each with distinct clinical prognoses. However, the available data on the clinicopathologic risks associated with several common PTC subtypes are controversial and require more comprehensive evaluation. To address this, we conducted a systematic search of English-language databases, including PubMed, EMbase, Cochrane Library, and Web of Science, for studies on six PTC subtypes, including classic papillary thyroid carcinoma (CPTC), papillary thyroid microcarcinoma (PTMC), follicular variant of papillary thyroid carcinoma (FVPTC), tall cell variant of papillary thyroid carcinoma (TCVPTC), diffuse sclerosing variant of papillary thyroid carcinoma (DSVPTC), and columnar cell papillary thyroid carcinoma (CCVPTC). Our case-control study of clinicopathological prognostic analyses of six subtypes, with a search date of January 2000 to May 2024. Two researchers independently screened the literature, extracted data, and assessed quality and risk of bias according to set criteria. R software gemtc package, Stata 15.1 software were applied to perform reticulated Meta-analysis methods were applied to compare the clinicopathological features and prognostic assessment of classic papillary thyroid carcinoma and the other five subtypes in all the studies.The risk of distant metastasis was higher in patients with CCVPTC, TCVPTC, and DSVPTC than in CPTC.FVPTC and PTMC exhibit a lower risk of in situ tumor relapse compared to CPTC. The tumour size of TCVPTC was significantly larger than that of CPTC, while there was no significant difference in the tumour size of CCV, DSV, FVPTC, CPTC and PTMC. DSVPTC was significantly more multifocal than the other subtypes. This network meta-analysis confirms the aggressive biological behavior and poor prognosis associated with TCVPTC, DSVPTC, and CCVPTC. Therefore, these subtypes should be managed aggressively with total thyroidectomy and lymph node dissection if diagnosed preoperatively. In contrast, FVPTC and PTMC are less aggressive and have a better prognosis, suggesting that treatment and follow-up strategies for PTC should be tailored according to the histopathological subtype.

Indexed as

Thyroid Cancer, PapillaryThyroid NeoplasmsHumansPrognosisRisk AssessmentThyroidectomyClassic papillary thyroid carcinoma (CPTC)Columnar cell variant (CCVPTC)Diffuse sclerosing variant (DSVPTC)Follicular variant (FVPTC)Histopathological subtypesPapillary thyroid carcinoma (PTC)Papillary thyroid microcarcinoma (PTMC)Prognostic factorsTall cell variant (TCVPTC)

Identifiers

PMID40853492
PMCPMC12378718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.